Skip to content

Study · Observational study · n = 1 · 2014

1 result

Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty.

Lee JW, Kim HJ, Choe YM, Kang HS, Kim SK, Jun YH, Lee JE

Annals of pediatric endocrinology & metabolism30 Sept 2014Cited by 28 (Europe PMC)

PMID25346917 (opens in a new tab)PMCIDPMC4208261 (opens in a new tab)DOI10.6065/apem.2014.19.3.135 (opens in a new tab)PepBankPUB-25346917
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studySafety outcome

    In a child treated for early puberty, anaphylaxis occurred after the sixth monthly depot triptorelin administration.

    In plain wordsIn a child treated for early puberty, anaphylaxis occurred after the sixth monthly depot triptorelin administration.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableAnaphylaxis after triptorelin
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Anaphylaxis occurred after the 6th administration of the monthly depot triptorelin acetate.
    2 context sentences
    Summary · context
    Anaphylaxis occurred in only one patient, and unilateral slipped capital femoral epiphysis (SCFE) in another one patient.
    Summary · context
    This retrospective study included children with CPP and early onset puberty, who were administered monthly with long-acting GnRHa (leuprolide acetate, triptorelin acetate) at the outpatient clinic of Department of Pediatrics, at Inha University Hospital, between January 2011 and December 2013.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.